Semnur Pharmaceuticals touted data today from a Phase I/II pharmacokinetic trial of its injectable, non-opioid pain-killer, SP-102. The trial enrolled 12 patients with radicular pain.
The trial met its primary endpoint and showed that single epidural injection of SP-102 could provide a sustained analgesic effect for 1 month.
Get the full story at our sister site, Drug Delivery Business News.
The post Semnur touts Phase I/II trial of non-opioid pain-killer appeared first on MassDevice.
from MassDevice http://ift.tt/2rTVd60
Cap comentari:
Publica un comentari a l'entrada